5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial

Cancer

Volumn 121, Issue 15, 2015, Pages 2537-2543

  Wagner Johnston, Nina D ^a   Sloan, Jeff A ^b   Liu, Heshan ^b   Kearns, Ann E ^b   Hines, Stephanie L ^b   Puttabasavaiah, Suneetha ^b   Dakhil, Shaker R ^c   Lafky, Jacqueline M ^b   Perez, Edith A ^b   Loprinzi, Charles L ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

Author keywords

bone loss; breast cancer; letrozole; postmenopausal; tamoxifen; zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; LETROZOLE; NITRILE; TAMOXIFEN; TRIAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; AGED; BONE DENSITY; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NITRILES; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 84937518556     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29327     Document Type: Article

References (21)

1. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1.2014. Available at: nccn.org. Accessed December 30, 2013.
2. Goss PE, Ingle JN, Martino S, et al., Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97: 1262-1271.
3. Howell A, Cuzick J, Baum M, et al., Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 60-62.
4. Breast International Group (BIG) 1-98 Collaborative Group, Thurlimann B, Keshaviah A, et al., A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353: 2747-2757.
5. Coates AS, Keshaviah A, Thurlimann B, et al., Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007; 25: 486-492.
6. Coombes RC, Hall E, Gibson LJ, et al,; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 1081-1092.
7. Goss PE, Ingle JN, Martino S, et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349: 1793-1802.
8. Perez EA, Josse RG, Pritchard KI, et al., Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006; 24: 3629-3635.
9. Brufsky AM, Harker WG, Beck JT, et al., Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012; 118: 1192-1201.
10. Brufsky A, Harker WG, Beck JT, et al., Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007; 25: 829-836.
11. Hines SL, Mincey B, Dentchev T, et al., Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009; 117: 603-609.
12. Coleman R, de Boer R, Eidtmann H, et al., Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013; 24: 398-405.
13. Llombart A, Frassoldati A, Paija O, et al., Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012; 12: 40-48.
14. Marshall D, Johnell O, Wedel H,. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996; 312: 1254-1259.
15. Bonnick SL, Johnston CC Jr, Kleerekoper M, et al., Importance of precision in bone density measurements. J Clin Densitom. 2001; 4: 105-110.
16. Baum M, Budzar AU, Cuzick J, et al., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359: 2131-2139.
17. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al., Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008; 9: 45-53.
18. Valachis A, Polyzos NP, Coleman RE, et al., Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013; 18: 353-361.
19. Coleman RE, Marshall H, Cameron D, et al,; AZURE Investigators. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011; 365: 1396-1405.
20. Gnant M, Mlineritsch B, Stoeger H, et al,; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011; 12: 631-641.
21. Coleman R, Gnant M, Paterson A, et al., Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomized trials [abstract]. Cancer Res. 2013; 73 (suppl 24):Page. Abstract, S4-07.